Open Access. Powered by Scholars. Published by Universities.®
Medical Biomathematics and Biometrics Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Biostatistics (2)
- Physical Sciences and Mathematics (2)
- Statistics and Probability (2)
- Biochemical Phenomena, Metabolism, and Nutrition (1)
- Biochemistry (1)
-
- Biochemistry, Biophysics, and Structural Biology (1)
- Bioinformatics (1)
- Biological Phenomena, Cell Phenomena, and Immunity (1)
- Biology (1)
- Biotechnology (1)
- Cancer Biology (1)
- Cell and Developmental Biology (1)
- Computational Biology (1)
- Genetic Processes (1)
- Genetic Structures (1)
- Genetics (1)
- Genetics and Genomics (1)
- Genomics (1)
- Integrative Biology (1)
- Life Sciences (1)
- Medical Biotechnology (1)
- Medical Genetics (1)
- Medical Molecular Biology (1)
- Medical Pathology (1)
- Medical Specialties (1)
- Molecular Genetics (1)
- Oncology (1)
Articles 1 - 3 of 3
Full-Text Articles in Medical Biomathematics and Biometrics
Assessing The Adequacy Of A Prediction Model, Abhaya Indrayan, Sakshi Mishra Ms
Assessing The Adequacy Of A Prediction Model, Abhaya Indrayan, Sakshi Mishra Ms
COBRA Preprint Series
No abstract provided.
Supervised Dimension Reduction For Large-Scale "Omics" Data With Censored Survival Outcomes Under Possible Non-Proportional Hazards, Lauren Spirko-Burns, Karthik Devarajan
Supervised Dimension Reduction For Large-Scale "Omics" Data With Censored Survival Outcomes Under Possible Non-Proportional Hazards, Lauren Spirko-Burns, Karthik Devarajan
COBRA Preprint Series
The past two decades have witnessed significant advances in high-throughput ``omics" technologies such as genomics, proteomics, metabolomics, transcriptomics and radiomics. These technologies have enabled simultaneous measurement of the expression levels of tens of thousands of features from individual patient samples and have generated enormous amounts of data that require analysis and interpretation. One specific area of interest has been in studying the relationship between these features and patient outcomes, such as overall and recurrence-free survival, with the goal of developing a predictive ``omics" profile. Large-scale studies often suffer from the presence of a large fraction of censored observations and potential …
Dose Expansion Cohorts In Phase I Trials, Alexia Iasonos, John O'Quigley
Dose Expansion Cohorts In Phase I Trials, Alexia Iasonos, John O'Quigley
Memorial Sloan-Kettering Cancer Center, Dept. of Epidemiology & Biostatistics Working Paper Series
A rapidly increasing number of Phase I dose-finding studies, and in particular those based on the standard 3+3 design, frequently prolong the study and include dose expansion cohorts (DEC) with the goal to better characterize the toxicity profiles of experimental agents and to study disease specific cohorts. These trials consist of two phases: the usual dose escalation phase that aims to establish the maximum tolerated dose (MTD) and the dose expansion phase that accrues additional patients, often with different eligibility criteria, and where additional information is being collected. Current protocols typically do not specify whether the MTD will be updated …